Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

7/22/24 4:10:52 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JAGX alert in real time by email

SC 13G/A 1 jagx.txt 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C805 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 18, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).? CUSIP No. 47010C805 13G Page 2 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Iliad Research & Trading, L.P. 11-3688679 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Utah NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) PN FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 3 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Iliad Management, LLC 20-0411071 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 4 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Fife Trading, Inc. 36-4151891 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Illinois NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) CO FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 5 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John M. Fife 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) IN FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 6 of 9 Pages Item 1. (a) Name of Issuer Jaguar Health, Inc. (b) Address of Issuer?s Principal Executive Offices 200 Pine Street, Suite 400 San Francisco, CA 94104 Item 2. (a) Name of Person Filing This report is filed by Iliad Research and Trading, LP, Iliad Management, LLC, Fife Trading, Inc., and John M. Fife with respect to the shares of Common Stock, $0.0001 par value per share, of the Issuer that are directly beneficially owned by Iliad Research and Trading, LP and indirectly beneficially owned by the other reporting and filing persons. (b) Address of the Principal Office or, if none, residence 303 East Wacker Drive, Suite 1040, Chicago, IL 60601 (c) Citizenship Iliad Research and Trading, LP is a Utah limited partnership. Iliad Management, LLC is a Delaware limited liability company. Fife Trading, Inc. is an Illinois corporation. John M. Fife is a United States citizen. (d) Title of Class of Securities Common Stock $0.0001 par value per share (e) CUSIP Number 47010C805 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G); (h) ? A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 795,743 (b) Percent of class: 9.13% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 795,743 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 795,743 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 47010C805 13G Page 9 of 9 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 7/22/2024 Date Iliad Research & Trading, L.P. /s/ John Fife Signature John Fife/President Name/Title Iliad Management, LLC /s/ John Fife Signature John Fife/President Name/Title Fife Trading, Inc. /s/ John Fife Signature John Fife/President Name/Title John M. Fife /s/ John Fife Signature John Fife Name/Title

Get the next $JAGX alert in real time by email

Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

Chat with this insight

Recent Analyst Ratings for
$JAGX

$JAGX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Lizak Carol R. was granted 4,280 shares, increasing direct ownership by 25,176% to 4,297 units (SEC Form 4)

Chief Scientific Officer Chaturvedi Pravin R was granted 4,922 shares, increasing direct ownership by 14,063% to 4,957 units (SEC Form 4)

Officer Wolin Jonathan S. was granted 4,922 shares, increasing direct ownership by 14,915% to 4,955 units (SEC Form 4)

$JAGX
Financials

Live finance-specific insights

Jaguar Health Reports 2020 Financial Results and Business Updates

$JAGX
Press Releases

Fastest customizable press release news feed in the world

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

$JAGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Jaguar Health with a new price target

$JAGX
Leadership Updates

Live Leadership Updates

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

$JAGX
SEC Filings

$JAGX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form PRE 14A filed by Jaguar Health Inc.

SEC Form SCHEDULE 13G filed by Jaguar Health Inc.

Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits